6.53
-0.49 (-6.98%)
| Previous Close | 7.02 |
| Open | 6.92 |
| Volume | 263,268 |
| Avg. Volume (3M) | 154,521 |
| Market Cap | 134,745,248 |
| Price / Book | 47.17 |
| 52 Weeks Range | |
| Earnings Date | 14 Aug 2023 - 18 Aug 2023 |
| Diluted EPS (TTM) | -0.780 |
| Total Debt/Equity (MRQ) | 56.38% |
| Current Ratio (MRQ) | 0.540 |
| Operating Cash Flow (TTM) | -30.01 M |
| Levered Free Cash Flow (TTM) | -18.54 M |
| Return on Assets (TTM) | -178.72% |
| Return on Equity (TTM) | -916.17% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Reviva Pharmaceuticals Holdings | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | -4.0 |
| Insider Activity | NA |
| Price Volatility | -5.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | -1.75 |
|
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer’s disease and Parkinson’s disease psychosis and its other drug candidate is RP1208. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 10.30% |
| % Held by Institutions | 20.35% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 7.00 (Benchmark, 7.20%) | Not Rated |
| Median | 3.00 (-54.06%) | |
| Low | 2.00 (Maxim Group, -69.37%) | Buy |
| Average | 3.75 (-42.57%) | |
| Total | 3 Buy, 1 Not Rated | |
| Avg. Price @ Call | 0.505 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Benchmark | 15 Sep 2025 | 7.00 (7.20%) | Not Rated | 0.440 |
| D. Boral Capital | 18 Aug 2025 | 3.00 (-54.06%) | Buy | 0.520 |
| 27 Jun 2025 | 3.00 (-54.06%) | Buy | 0.340 | |
| Roth Capital | 18 Aug 2025 | 3.00 (-54.06%) | Buy | 0.520 |
| Maxim Group | 15 Aug 2025 | 2.00 (-69.37%) | Buy | 0.540 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 14 Aug 2025 | Announcement | Reviva Reports Second Quarter 2025 Financial Results and Recent Business Highlights |
| 26 Jun 2025 | Announcement | Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering |
| 25 Jun 2025 | Announcement | Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |